15 12.º FORO DE Inmunología Traslacional e INMUNOTERAPIA DEL CÁNCER 10.45-11.15 Special Session: Meet the translational expert Chair: Dr. Luis de la Cruz Merino. Hospital Universitario Virgen Macarena. Sevilla 10.45-10.55 Impact of T-cell bispecific treatment on the tumor immune microenvironment Dr. Peter Kirk. PhD. Director, Translational Medicine Immunocore Limited. Oxon, U.K. 10.55-11.05 Discussion 11.05-11.35 Poster display and coffee CP-10 CIRCULATING EPIGENETIC PROFILING IDENTIFIES PTPRT, PRDM1, AND PTPRS AS PREDICTIVE AND DYNAMIC BIOMARKERS OF RESPONSE TO IMMUNE CHECKPOINT INHIBITORS IN NSCLC Onieva Zafra, JL1; Pérez-Ruiz, E2; Figueroa-Ortiz, L1; Zafra, J3; Martínez-Gálvez, B4; Benítez-Montañez, JC1; Rodríguez Martínez, A1; Rueda-Domínguez, A1; Barragán, I1 1Group of Translational Research in Cancer Immunotherapy and Epigenetics. Medical Oncology Unit. Hospital Universitario Virgen de la Victoria. Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina. Málaga. 2Group of Translational Research in Cancer Immunotherapy and Epigenetics.Medical Oncology Unit. Hospital Regional de Málaga. Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina. Málaga. 3Group of Translational Research in Cancer Immunotherapy and Epigenetics. Radiation Oncology Unit. Hospital Universitario Virgen de la Victoria. Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina. Málaga. 4Group of Translational Research in Cancer Immunotherapy and Epigenetics. Medical Oncology Unit. Hospital Universitario Virgen de la Victoria. Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina. Málaga CP-11 SYSTEMIC IMMUNE DYNAMICS ASSOCIATED WITH PATHOLOGICAL RESPONSE IN BREAST CANCER (BC) PATIENTS RECEIVING NEOADJUVANT THERAPY (NAT) Silva Romeiro, S; Jiménez Cortegana, C; Sánchez León, ML; Palazón Carrión, N; Flores Campos, R; Sánchez Margalet, V; de la Cruz Merino, L Hospital Universitario Virgen Macarena. Sevilla CP-12 TARGETING TUMOR-ASSOCIATED MYELOID CELLS ENHANCES NKG2D-CAR T CELL EFFICACY IN PEDIATRIC OSTEOSARCOMA MODELS Márquez Cantudo, M1; Hidalgo, L2; García-Rodríguez, P1; Zubizarreta, M1; Luengo, A1; García-Castro, J1 1Instituto de Salud Carlos III (ISCIII). Madrid. 2Instituto de Salud Carlos III (ISCIII). Biomedical Innovation Unit. Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT). Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Madrid
RkJQdWJsaXNoZXIy MTQzMjMwMg==